Direct grants, selective tax advantages and advance payments: Member states will be able to set up schemes to grant up to EUR800,000 to a company to address its urgent liquidity needs.

State guarantees for loans taken by companies from banks: Member states will be able to provide State guarantees to ensure banks keep providing loans to the customers who need them.

Subsidised public loans to companies: Member states will be able to grant loans with favourable interest rates to companies. These loans can help businesses cover immediate working capital and investment needs.

Safeguards for banks that channel State aid to the real economy: Some member states plan to build on banks' existing lending capacities, and use them as a channel for support to businesses, in particular to small and medium-sized companies. The Temporary Framework makes clear that such aid is considered as direct aid to the banks' customers, not to the banks themselves, and gives guidance on how to ensure minimal distortion of competition between banks.

Short-term export credit insurance: The Framework introduces additional flexibility on how to demonstrate that certain countries are not-marketable risks, thereby enabling short-term export credit insurance to be provided by the state where needed.

Support for coronavirus related research and development (R&D): to address the current health crisis, member states can grant aid in the form of direct grants, repayable advances or tax advantages for coronavirus and other relevant antiviral R&D. A bonus may be granted for cross-border co-operation projects between member states.

Support for the construction and upscaling of testing facilities: member states can grant aid in the form of direct grants, tax advantages, repayable advances and no-loss guarantees to support investments enabling the construction or upscaling of infrastructures needed to develop and test products useful to tackle the coronavirus outbreak, up to first industrial deployment. These include medicinal products (including vaccines) and treatments; medical devices and equipment (including ventilators and protective clothing, as well as diagnostic tools); disinfectants; data collection and processing tools useful to fight the spread of the virus. To encourage co-operation and to support quick action, companies can benefit from a bonus when their investment is supported by more than one member state and when the investment is concluded within two months after the granting of the aid.

Support for the production of products relevant to tackle the coronavirus outbreak: member states can grant aid in the form of direct grants, tax advantages, repayable advances and no-loss guarantees to support investments enabling the rapid production of coronavirus-relevant products (as listed in Support for the construction and upscaling of testing facilities, above). To encourage co-operation and to support quick action, companies may benefit from a bonus when their investment is supported by more than one member state and when the investment is concluded within two months after the granting of the aid.

Targeted support in the form of deferral of tax payments and/or suspensions of social security contributions: to further reduce the liquidity constraints on companies due to the coronavirus crisis and to preserve employment, member states can grant targeted deferrals of payment of taxes and of social security contributions in those sectors, regions or for types of companies that are hit the hardest by the outbreak.

Targeted support in the form of wage subsidies for employees: to help limit the impact of the coronavirus crisis on workers, member states can contribute to the wage costs of those companies in sectors or regions that have suffered most from the coronavirus outbreak, and would otherwise have had to lay off personnel.